News & Updates

Diabetes in family does not increase risk of CVD

27 Sep 2020

A family history of diabetes appears to be unrelated to the risk of incident cardiovascular disease (CVD), reports a recent study. Parental myocardial infarction (MI) or stroke, however, may be linked to CVD onset.

Diabetes in family does not increase risk of CVD

27 Sep 2020

PCI tied to death, MI, stroke in patients with LMCA, LV dysfunction

26 Sep 2020

Percutaneous coronary intervention (PCI), compared with coronary artery bypass grafting (CABG), in the revascularization of left main coronary artery (LMCA) disease may lead to death, myocardial infarction (MI), or stroke in patients with moderate or severe left ventricular (LV) dysfunction, reveals a study.

PCI tied to death, MI, stroke in patients with LMCA, LV dysfunction

26 Sep 2020

TAVR may improve kidney function in patients with aortic stenosis

26 Sep 2020

Patients with severe aortic stenosis who undergo transcatheter aortic valve replacement (TAVR), even with baseline impaired estimated glomerular filtration rate (eGFR), are more likely to improve or maintain their chronic kidney disease (CKD) stage rather than make it worse, a study has shown.

TAVR may improve kidney function in patients with aortic stenosis

26 Sep 2020

Preterm birth leaves lasting impressions on heart

26 Sep 2020

Infants born preterm and with very low birthweight (VLBW) appear to sustain altered cardiovascular structure and function in adulthood, a new study has found.

Preterm birth leaves lasting impressions on heart

26 Sep 2020

Old drug, new tricks: Colchicine for chronic coronary disease

25 Sep 2020 by

Low-dose colchicine reduced the risk of multiple cardiovascular (CV) outcomes in patients with chronic coronary disease, according to the LoDoCo2* trial presented at ESC 2020.

Old drug, new tricks: Colchicine for chronic coronary disease

25 Sep 2020

Inhaled treprostinil ups exercise capacity in pulmonary hypertension

25 Sep 2020 by

Inhaled treprostinil significantly improves exercise capacity in terms of 6-minute walking distance (6MWD) over 16 weeks compared with placebo in patients with pulmonary hypertension associated with interstitial lung disease (ILD), according to the INCREASE trial presented at ATS 2020.

Inhaled treprostinil ups exercise capacity in pulmonary hypertension

25 Sep 2020

Anxiety, depression link to aortic stiffness suggests brain–gut–vascular axis in CD

25 Sep 2020

The associations of anxiety, depression, and chronic inflammation with aortic pulse wave velocity (aPWV) and systolic blood pressure (SBP) indicate the first evidence of a brain–gut–vascular axis and new potential targets for treatment in patients with Crohn’s disease (CD), reveals a study.

Anxiety, depression link to aortic stiffness suggests brain–gut–vascular axis in CD

25 Sep 2020

Strength training helps lower blood pressure

24 Sep 2020

A recent study has shown the effectiveness of strength training in reducing both systolic (SBP) and diastolic blood pressures (DBP).

Strength training helps lower blood pressure

24 Sep 2020

Empagliflozin reduces CV death, HF hospitalization in HFrEF patients

23 Sep 2020 by

In patients with chronic heart failure with reduced ejection fraction (HFrEF), empagliflozin reduced the risk of cardiovascular (CV) death or heart failure hospitalization (HHF) and decline in estimated glomerular filtration rate (eGFR), results of the EMPEROR-Reduced* trial showed.

Empagliflozin reduces CV death, HF hospitalization in HFrEF patients

23 Sep 2020

DAPA-CKD heralds a new era for dapagliflozin in kidney disease

23 Sep 2020 by

Adding dapagliflozin to standard of care (SOC) significantly reduces the risk of worsening kidney function, death due to kidney or cardiovascular (CV) disease, and all-cause mortality compared with SOC alone in patients with chronic kidney disease (CKD), regardless of whether they have type 2 diabetes (T2D), reveals the DAPA-CKD* trial — showing dapagliflozin charting new territories from diabetes to the renal realm.

DAPA-CKD heralds a new era for dapagliflozin in kidney disease

23 Sep 2020

News & Updates

Filter by Specialty:

Specialty:

Diabetes in family does not increase risk of CVD

Diabetes in family does not increase risk of CVD

PCI tied to death, MI, stroke in patients with LMCA, LV dysfunction

PCI tied to death, MI, stroke in patients with LMCA, LV dysfunction

TAVR may improve kidney function in patients with aortic stenosis

TAVR may improve kidney function in patients with aortic stenosis

Preterm birth leaves lasting impressions on heart

Preterm birth leaves lasting impressions on heart

Old drug, new tricks: Colchicine for chronic coronary disease

Old drug, new tricks: Colchicine for chronic coronary disease

Inhaled treprostinil ups exercise capacity in pulmonary hypertension

Inhaled treprostinil ups exercise capacity in pulmonary hypertension

Anxiety, depression link to aortic stiffness suggests brain–gut–vascular axis in CD

Anxiety, depression link to aortic stiffness suggests brain–gut–vascular axis in CD

Strength training helps lower blood pressure

Strength training helps lower blood pressure

Empagliflozin reduces CV death, HF hospitalization in HFrEF patients

Empagliflozin reduces CV death, HF hospitalization in HFrEF patients

DAPA-CKD heralds a new era for dapagliflozin in kidney disease

DAPA-CKD heralds a new era for dapagliflozin in kidney disease